COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,711 Articles (22,913 medRxiv, 8,798 bioRxiv)

Most recent first Previous |  Page 20: Articles 191-200  | Next

Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead
Elshan, N. G. R. D., Wolff, K. C., Weiss, F., Ghorai, S., Grabovyi, G., Wilson, K., Riva, L., Woods, A. K., Pedroarena, J., Nazarian, A., Liu, Y., Mazumdar, W., Song, L., Okwor, N., Malvin, J., Bakowski, M. A., Kirkpatrick, M. G., Gebara-Lamb, A., Huang, E., Nguyen-Tran, V. T. B., Chi, V., Li, S., Lee, K.-J., McNamara, C. W., Gupta, A. K., Rahimi, A., Chen, J. J., Joseph, S. B., Schultz, P. G., Chatterjee, A. K.
10.64898/2026.05.15.725542 — Posted: 2026-05-18
Environmental stochasticity can account for patterns of within-host respiratory virus evolution
Xiao, W. F., Farjo, M. N., Lowen, A. C., Koelle, K.
10.64898/2026.05.15.725410 — Posted: 2026-05-18
Who infected the reported cases? Evidence from 678,482 COVID-19 cases with identified infector collected in routine surveillance in the Netherlands, 2020-2022.
Backer, J. A., Leung, K. Y., Andeweg, S. P., Van de Kassteele, J., Veldhuijzen, I., Hahne, S., Wallinga, J.
10.64898/2026.05.15.26347859 — Posted: 2026-05-17
Expansion Revealing of Pathology Resolves Nanostructures Associated with Inflammatory Phenotypes in COVID-19 Decedent Human Brain Tissue
Stanton, A. E., Kang, J., Blanchard, J. W., Boix, C. A., Schroeder, M. E., Lee, Y., Su, H., Wang, S., Yu, E., Emenari, A., Peng, Z., Agbas, E., Cerit, O., Park, D., Zhang, R., Bennett, D. A., Yin, P., Kellis, M., Langer, R., Boyden, E., Tsai, L.-H.
10.64898/2026.05.14.725177 — Posted: 2026-05-15
A Structural Domain in the genomic RNA of SARS-CoV-2 Folds into a Compact Granular Structure without the N protein: A Single-Molecule Fluorescence Spectroscopic Investigation
Kimura, T., Katayama, T., Ishikawa, S., Mitra, S., Yamano, Y., Onizuka, K., Nagatsugi, F., Laha, S., Naganathan, A. N., Itoh, Y., Takahashi, S.
10.64898/2026.05.15.725307 — Posted: 2026-05-15
Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses
Kumar, S., Lai, L., Ellis, M., Patel, A. B., Joshi, D. J., Velden, J. V., Faraj, J. Z. A., Wimalasena, S. T., Pallavi, R. R., Iriss, J., Bechnak, K., Edupuganti, S., Rouphael, N., Ortlund, E., Moreno, A., Menachery, V. D., Zarnitsyna, V. I., Wrammert, J., Suthar, M. S.
10.64898/2026.05.13.725047 — Posted: 2026-05-15
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial
Trujillo Llano, C., Fromm, A. E., Lingemann, L., Grittner, U., Meinzer, M. F., Fleischmann, R., Brakemeier, E.-L., Antonenko, D. F., Floeel, A.
10.64898/2026.05.11.26352906 — Posted: 2026-05-14
Pathogen-specific host responses define distinct pneumonia endotypes in the human lung
Markov, N. S., Mozejko, M., Guggilla, V., Łazecka, M., Donnelly, H. K., Donayre, A., Fenske, S., Peltekian, A., Puczko-Szymanski, B., Szymczak, P., Izdebski, A., Luo, L., Senkow, K. J., Cusick, L., Yu, Z., Swaminathan, S., Lu, Z., Abdala-Valencia, H., Phan, D., Clepp, R. K., Rasmussen, L. V., Pawlowski, A., Pickens, C. O., Nadig, N. R., Walunas, T., Tighe, R., The Neu-Lung Investigators, , Wunderink, R. G., Budinger, G. S., Morales-Nebreda, L., Gao, C. A., Singer, B. D., Misharin, A. V., Szczurek, E., The NU SCRIPT Study Investigators
10.64898/2026.05.12.724509 — Posted: 2026-05-14
Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability
He, L., Su, Y.-W. N., Zhang, F., Moustafa Abdelrady, I., Gohara, D. W., Ye, C., Martinez-Sobrido, L., Arnold, J. J., Cameron, C. E., Xiang, Y.
10.64898/2026.05.12.724615 — Posted: 2026-05-12
Independent Validation of Test-Adjusted COVID-19 Incidence Estimates Using Wastewater Surveillance Data in Ontario, Canada
Fisman, D., Wilson, N., Lee, C. E., Tuite, A.
10.64898/2026.05.08.26352754 — Posted: 2026-05-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).